AlphaTON Capital 在 Consensus 香港大會上：揭曉面向 10 億用戶的保密人工智能基礎設施

Core Insights - AlphaTON Capital Corp is expanding its Telegram super app to reach over 1 billion monthly active users, showcasing its strategic focus on decentralized AI and privacy protection technologies at the Consensus Hong Kong conference [1][7] - The company aims to build a critical infrastructure layer that will power a new generation of financial, business, and AI-driven services within the Telegram ecosystem [1] Group 1: Event Participation - AlphaTON Capital will participate in the Consensus Hong Kong conference on February 11-12, 2026, highlighting its strategies and innovations in the field of privacy-preserving AI [1] - Anthony Scaramucci, a strategic advisor for AlphaTON, will discuss the rapid digital transformation of global finance through blockchain and AI adoption during the conference [2] - Brittany Kaiser, CEO of AlphaTON, will present on the Cocoon AI initiative, focusing on how the company is building infrastructure to support privacy-preserving AI for Telegram users [3] Group 2: Strategic Partnerships and Innovations - The collaboration with Midnight Foundation aims to develop the first privacy-preserving AI infrastructure specifically for Telegram, ensuring users have control over their personal data [4] - The integration with Midnight positions AlphaTON as a key driver of ecosystem growth, transforming Telegram into a hub for advanced privacy protection technologies [4] - AlphaTON is poised to capture significant market opportunities in the confidential AI sector, which is projected to have a potential value in the trillions of dollars [4] Group 3: Company Overview - AlphaTON Capital Corp is a leading technology company listed on Nasdaq (ATON), focusing on expanding the Telegram ecosystem and integrating AI-driven services [7] - The company operates under the leadership of CEO Brittany Kaiser and aims to provide institutional-level participation in the Telegram ecosystem while adhering to Nasdaq governance standards [7] - AlphaTON is also involved in drug development and strategic consulting, aiming to enhance patient quality of life through innovative therapies [8]